Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $24000.0.

  • Niagen Bioscience's Capital Expenditures fell 4146.34% to $24000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $260000.0, marking a year-over-year increase of 12608.7%. This contributed to the annual value of $163000.0 for FY2024, which is 1013.51% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Capital Expenditures is $24000.0, which was down 4146.34% from $135000.0 recorded in Q2 2025.
  • Niagen Bioscience's Capital Expenditures' 5-year high stood at $265000.0 during Q2 2021, with a 5-year trough of $2000.0 in Q4 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $41000.0 (2024), whereas its average is $65526.3.
  • Per our database at Business Quant, Niagen Bioscience's Capital Expenditures crashed by 9926.2% in 2021 and then skyrocketed by 850000.0% in 2022.
  • Quarter analysis of 5 years shows Niagen Bioscience's Capital Expenditures stood at $2000.0 in 2021, then surged by 8500.0% to $172000.0 in 2022, then plummeted by 87.79% to $21000.0 in 2023, then skyrocketed by 228.57% to $69000.0 in 2024, then crashed by 65.22% to $24000.0 in 2025.
  • Its Capital Expenditures was $24000.0 in Q3 2025, compared to $135000.0 in Q2 2025 and $32000.0 in Q1 2025.